News

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following the U.S. Food and Drug Administration’s (FDA) recent announcement outlining scientific and technical steps to transition from animal testing to New Approach Methodologies (NAMs) for safety assessments of drug products:

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today released the following statement echoing concerns U.S. Reps. Bob Latta (OH-05), Dan Crenshaw (TX-02), and Mariannette Miller-Meeks (IA-01) raised to the U.S. Food and Drug Administration (FDA), urging the Agency to strike the simultaneous marketing portion of the preamble that is tied to the final rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU):

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today released the following statement echoing concerns U.S. Reps. Bob Latta (OH-05), Dan Crenshaw (TX-02), and Mariannette Miller-Meeks (IA-01) raised to the U.S. Food and Drug Administration (FDA), urging the Agency to strike the simultaneous marketing portion of the preamble that is tied to the final rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU):